维普期刊资源整合服务平台（V6.5）

22篇 您的检索式：作者名="SCHLOSSMAN RL"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Thalidomide,lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma显示文摘	LAUBACH JP SCHLOSSMAN RL MITSIADES CS		0，，01：	1
2	Immunomodulatory dr-ug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma显示文摘	Richardson PG Schlossman RL Weller E	2002	Blood2002，100，：	1
3	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma显示文摘	Richardson PG Schlossman RL Weller E	2002	Blood2002，100，9：	1
4	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma 显示文摘	RICHARDSON PG SCHLOSSMAN RL WELLER E	2002	Blood2002，100，9：	1
5	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma显示文摘	Richardson PG Schlossman RL Weller E	2002	Blood2002，100，9：	1
6	Thalid- omide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma显示文摘	Laubach JP Schlossman RL Mitsiades CS	2011	Expert Rev He- matol2011，4，1：	1
7	Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia显示文摘	Richardson PG Laubach JP Schlossman RL	2010	J Natl Compr Canc Netw2010，8，：	1
8	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma显示文摘	RICHARDSON PG SCHLOSSMAN RL WELLER E	2002	Blood2002，100，9：	1
9	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma显示文摘	Richardson PC Schlossman RL Weller E	2002	Bloed2002，100，9：	1
10	Role of TNF-a in the pathophysiology of human multiple myeloma: therapeutic applications 显示文摘	Hideshima T Chauhan D Schlossman RL	2001	Oncogene2001，20，：	1
11	Phase II trial of single agent bortezomib (VELCADE) in patients with previously untreated multiple myeloma显示文摘	Richardson PG Chanan-Khan A Schlossman RL	2004	Blood2004，104，3：	1
12	Phase II trial of single agent bortezomib (VELCADE) in patients with previously untreated multiple myeloma 显示文摘	Richardson PG Chanan-Khan A Schlossman RL	2004	Blood2004，104，3：	1
13	Immunomodulatory drug CC-5013 overcome drug resistance and is well tolerated in patients with relapsed multiple myeloma显示文摘	Richardson PG Schlossman RL Weller E	2002	Blood2002，100，9：	1
14	Thalid- omide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma显示文摘	Laubach JP Schlossman RL Mitsiades CS	2011	Expert Review of Hematology2011，4，1：	1
15	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed myeloma 显示文摘	Richardson PG Schlossman RL Weller E	2002	Blood2002，100，9：	1
16	Immunomodulatory drug CC-5013 overcomes drug resistance and is well toleratedin patients with relapsed multiple myeloma显示文摘	Richardson PG Schlossman RL Weller E	2002	Blood2002，100，9：	1
17	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma显示文摘	Schlossman RL Weller E	2002	Blood2002，100，：	1
18	Immunomodulatory drug CC - 5013 overcomes drug resistence and is well tolerated in patients qith relapsed multiple myeloma显示文摘	Richardson PG Schlossman RL Weller E	2002	Blood2002，100，9：	1
19	PANORAMA 2 : panobinostat in combination with bortczomih and dexamethasone in patients with relapsed and bortezomib-refractory myeloma显示文摘	RICHARDSON PG SCHLOSSMAN RL ALSINA M	2013	Blood2013，122，14：	1
20	Immunomodula- tory drug CC-5013 overcomes drug resistance and is well tolerat- ed in patients with relapsed multiple myeloma 显示文摘	Richardson PG Schlossman RL Weller E	2002	Blood2002，100，9：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示